Bispecific Antibodies Market By Type (Immunoglobulin G (IgG) Like Molecule, Non Immunoglobulin G (IgG) Like Molecule), by Application (Oncology, Autoimmune Disease, Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Industry Outlook

The bispecific antibodies market is set to grow with a compounded annual growth rate (CAGR) of 5.9% during the forecast period from 2018 to 2026. According to the research findings presented by the World Health Organization (WHO), in 2018 cancer is responsible for the death of approximately 9.6 million people throughout the globe. The severe adverse effects related to chemotherapy led to the development of bispecific antibodies for the treatment of cancer. Currently 2 drugs are approved by the U.S.FDA catumaxomab and blinatumomab. 30 bispecific antibodies are in the pipeline undergoing clinical trial studies. The competition exerted by monoclonal antibodies for the treatment of the same disease condition act as a major limitation for the bispecific antibodies market growth.

Market Synopsis

Bispecific Antibodies Market

Get a sample copy for more information

"Longer serum half-life and excellent cytotoxicity profile drive the IgG like molecule market"

Immunoglobulin G (IgG) like molecule is leading the type segment for bispecific antibodies market. IgG like molecule such as catumaxomab (Fresenius Biotech and Trion Pharma), is widely employed for the treatment of malignant ascites due to its inherent features such as longer serum half-life and excellent cytotoxicity profile. Non IgG like molecule will be the fastest growing market during the forecast period owing to the recent launch of blinatumomab (Amgen, Inc.) for the treatment of refractory B-cell acute lymphoblastic leukemia on account of its smaller half-life and enhanced tissue penetration characteristics.

Bispecific Antibodies Market

Get a sample copy for more information

"Severe adverse effect related to current treatment regime and burgeoning requirement for targeted drug delivery drive oncology market growth"

In the current scenario oncology is reigning the application segment for bispecific antibodies market. The factors responsible for its growth are the severe adverse effects related to current treatment regimen and burgeoning requirement of targeted drug delivery for the treatment of cancer. Bispecific antibodies has the ability to cater the current requirement in cancer treatment by redirecting immune effector cells towards tumor cells, blocking signaling pathways and targeting tumor angiogenesis. Autoimmune diseases such as plaque psoriasis and rheumatoid arthritis will be treated in the near future by employing bispecific antibodies such as IL-6R × HAS (Ablynx) and IL-17A/F (Merck Group) by blocking the proinflammatory cytokines. Few bispecific antibodies are in the pipeline which will be utilized for the treatment of ailments such as wet age related macular degeneration (AMD) and idiopathic pulmonary fibrosis.

Bispecific Antibodies Market

Get a sample copy for more information

"Increasing mortality and lack of effective treatment for cancer drive the Bispecific antibodies market in North America"

North America is currently leading the geographical segment for Bispecific antibodies market. The major attributes responsible for the dominance of North America are increasing mortality and lack of effective treatment for cancer. According to the Center for Disease Control and Prevention (CDC), cancer is the second largest cause of mortality in the United States, resulting in 1 in 4 deaths due to cancer. Bispecific antibodies market in Europe is driven by factors such as increased funding by government healthcare agencies in the drug discovery and cancer prevention program. Domicile of key players such as Merck Group, F.Hoffman La-Roche AG and Janssen Global Services, LLC., etc. provide impetus to the growth of Bispecific antibodies in Europe. Asia Pacific is set to register positive growth during the forecast period 2018 to 2026 owing to rising prevalence of cancer and supportive regulatory environment for the approval and distribution of bispecific antibodies.

Bispecific Antibodies Market

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

In the scope of the report the market is segmented as follows:

ATTRIBUTE DETAILS
Research Period  2016-2026
Base Year 2017
Forecast Period  2018-2026
Historical Year  2016
Unit  USD Million
Segmentation

 By Type (2016–2026; US$ Mn)
 • Immunoglobulin G (IgG) Like Molecule
 • Non Immunoglobulin G (IgG) Like Molecule

 By Application (2016–2026; US$ Mn)
 • Oncology
 • Autoimmune Disease
 • Others

 Geography Segment (2016–2026; US$ Mn)
 • North America (United States and Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of Asia Pacific)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of MEA)

Biopharmaceuticals companies providing Bispecific antibodies are Amgen, Inc., Ablynx, Eli Lilly and Company, F.Hoffman La-Roche AG, Janssen Global Services, LLC., Merck Group, Merrimack Pharmaceuticals, Neovii Biotech, OncoMed Pharmaceuticals, Inc. and Regeneron Pharmaceuticals.

Key questions answered in this report

  • Who are the key biopharmaceutical companies manufacturing bispecific antibodies?
  • What are the drivers, opportunities and restraints pertaining to the bispecific antibodies market?
  • What is the disease etiology of different forms of cancer and what is the mechanism of action of bispecific antibodies?
  • Which type is the largest and fastest growing in the bispecific antibodies market?
  • Which application is the largest and fastest growing in the bispecific antibodies market?
  • Which regional segment is the leading and fastest growing in the bispecific antibodies market?
Choose License Type
Published Date:  Dec 2018
Category:  Pharmaceuticals
Report ID:   59497
Report Format:   PDF
Pages:   120
Rating:    4.2 (49)
Connect With Us
+1-408-641-3282
24/7 Research Support